MedCheck: Psilocybin for Depression, LSD for Anxiety, Donanemab, LSD, and More
Psychiatric News April 23, 2024 DOI: 10.1176/appi.pn.2024.05.5.1 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | News report Peer reviewed |
|---|---|
| Sample size | 414 |
| Population | Adults with a history of bipolar I disorder |
| Duration | Four weeks of treatment, with difference evident after two weeks |
| Measures | Young Mania Rating Scale |
| Topics | Anxiety LSD Psilocybin Serotonin Depression |
| Keywords | Hallucinogen Depression economics Clinical psychology |
| Key points | In a phase 3 trial of 414 adults with bipolar I disorder, iloperidone produced a 14-point drop on the Young Mania Rating Scale after four weeks, compared with a 10-point drop for placebo, with a statistically significant difference in mania improvement evident after two weeks. The FDA approved iloperidone for acute treatment of manic or mixed episodes in adults with bipolar I disorder. |
Abstract
announced in April that the Food and Drug Administration (FDA) approved the antipsychotic Fanapt (iloperidone) for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. Iloperidone has been approved for the acute treatment of schizophrenia since 2009. The approval was based on a phase 3 clinical trial of 414 adults with a history of bipolar I disorder. After four weeks of treatment, patients treated with iloperidone exhibited a 14-point drop on the Young Mania Rating Scale, compared with a 10-point drop among patients taking placebo. A statistically significant difference in mania improvement between iloperidone and placebo was evident after two weeks.